



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

April 2019





HIV/AIDS Drug Treatment Program

Monthly Report

© 2019 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

April 2019

N = 7386



Health Authority	Male	Female	All
FRASER	1436	419	1855
INTERIOR	414	94	508
NORTHERN	123	82	205
VANCOUVER COASTAL	3407	444	3851
VANCOUVER ISLAND	764	164	928
	6144	1203	7347
		Unknown/not stated:	39
		Total:	7386

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (April 2014 - April 2019)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (April 2014 - April 2019)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (April 2014 - April 2019)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (April 2014 - April 2019)






1.6 Percent Distribution of Active Participants by CD4 Count (April 2014 - April 2019)






1.7 Percent Distribution of Inactive Participants by CD4 Count (April 2014 - April 2019)






1.8 Active and Inactive Participants (April 2014 - April 2019)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (April 2014 - April 2019)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (April 2014 - April 2019)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(April 2014 - April 2019)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (April 2014 - April 2019)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(April 2014 - April 2019)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (April 2014 - April 2019)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(April 2014 - April 2019)





1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (April 2014 - April 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(April 2014 - April 2019)



Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts (April 2014 - April 2019)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(April 2014 - April 2019)






1.20 Cumulative Resistance Testing Results by Resistance Category
(April 2014 - April 2019)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (April 2014 - April 2019)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2019
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	27	5	0	5	3	900	5	44	3
1988	28	6	0	6	6	510	6	<40	3
1989	26	54	1	55	44	470	54	<40	3
1990	25	52	1	53	43	490	52	<40	3
1991	25	38	3	41	31	570	39	<40	3
1992	25	63	5	68	48	585	65	<40	3
1993	24	134	16	150	131	560	142	<40	3
1994	22	80	13	93	76	550	90	<40	3
1995	22	129	21	150	122	565	141	<40	3
1996	20	349	57	406	331	590	382	<40	3
1997	18	292	35	327	281	590	313	<40	3
1998	17	200	40	240	202	540	228	<40	3
1999	18	167	37	204	166	565	194	<40	3
2000	18	127	34	161	139	580	155	<40	3
2001	17	127	31	158	127	550	149	<40	3
2002	16	122	24	146	119	580	143	<40	3
2003	16	158	27	185	152	620	177	<40	3
2004	14	170	41	211	174	600	201	<40	3
2005	14	190	44	234	179	590	215	<40	3
2006	13	188	39	227	187	590	214	<40	3
2007	12	256	50	306	249	620	282	<40	3
2008	11	298	67	365	300	670	347	<40	3
2009	10	325	71	396	327	670	376	<40	3
2010	9	275	66	341	282	640	323	<40	3
2011	8	338	75	413	341	680	390	<40	3
2012	7	278	66	344	284	700	323	<40	3
2013	6	277	68	345	282	651	323	<40	3
2014	5	289	53	342	272	720	316	<40	3
2015	4	295	52	347	289	660	330	<40	3
2016	3	286	60	346	284	650	324	<40	3
2017	2	248	38	286	241	640	268	<40	3
2018	1	238	57	295	249	600	283	<40	3
2019	0	90	17	107	99	520	105	<40	3
Total:		6144	1209	7353					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	7286	750	2384	<40	2109	610
FEB-2018	7251	762	1904	<40	1743	610
MAR-2018	7276	769	2050	<40	1829	610
APR-2018	7263	776	2081	<40	1842	620
MAY-2018	7285	772	2149	<40	1928	600
JUN-2018	7288	787	2008	<40	1792	610
JUL-2018	7291	786	2037	<40	1810	600
AUG-2018	7292	796	2093	<40	1874	618
SEP-2018	7246	796	2015	<40	1787	620
OCT-2018	7339	778	2170	<40	1942	610
NOV-2018	7343	785	2092	<40	1813	630
DEC-2018	7360	790	1747	<40	1533	620
JAN-2019	7399	793	2457	<40	2123	610
FEB-2019	7383	800	1855	<40	1551	620
MAR-2019	7427	791	2086	<40	1692	610
APR-2019	7386	797	2144	<40	1649	610

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	1424	3347	79	890	71	380
FEB-2018	1467	3115	79	1036	66	440
MAR-2018	1450	3236	75	59	70	485
APR-2018	1468	3174	72	634	63	497
MAY-2018	1452	3290	91	<40	82	455
JUN-2018	1461	3259	68	2980	64	440
JUL-2018	1467	3266	70	<40	55	570
AUG-2018	1499	3172	63	56	59	490
SEP-2018	1545	2986	88	220	82	415
OCT-2018	1473	3335	79	<50	69	350
NOV-2018	1483	3312	81	83	73	480
DEC-2018	1479	3347	57	355	46	495
JAN-2019	1469	3427	72	70	64	380
FEB-2019	1496	3344	73	108	64	590
MAR-2019	1458	3509	74	885	58	395
APR-2019	1493	3414	79	<50	67	500

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2018	7246	1424	12	12	192	126	56	13217
FEB-2018	7216	1467	11	27	125	168	-30	13254
MAR-2018	7237	1450	17	21	156	135	21	13281
APR-2018	7229	1468	13	15	153	159	-8	13303
MAY-2018	7254	1452	9	12	172	147	25	13328
JUN-2018	7251	1461	13	16	150	153	-3	13350
JUL-2018	7247	1467	13	13	159	155	-4	13376
AUG-2018	7256	1499	9	27	155	159	9	13415
SEP-2018	7209	1545	15	15	155	195	-47	13441
OCT-2018	7307	1473	8	19	218	127	98	13477
NOV-2018	7317	1483	5	9	172	163	10	13503
DEC-2018	7334	1479	11	19	152	142	17	13528
JAN-2019	7369	1469	14	20	191	160	35	13563
FEB-2019	7357	1496	7	16	161	178	-12	13592
MAR-2019	7391	1458	15	13	188	145	34	13612
APR-2019	7353	1493	9	15	149	176	-38	13639

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2018	58	6724	449	55	7286	0.80%	92.29%	6.16%	0.75%	100.00%
FEB-2018	62	6679	451	59	7251	0.86%	92.11%	6.22%	0.81%	100.00%
MAR-2018	62	6705	453	56	7276	0.85%	92.15%	6.23%	0.77%	100.00%
APR-2018	59	6697	449	58	7263	0.81%	92.21%	6.18%	0.80%	100.00%
MAY-2018	66	6706	455	58	7285	0.91%	92.05%	6.25%	0.80%	100.00%
JUN-2018	61	6721	448	58	7288	0.84%	92.22%	6.15%	0.80%	100.00%
JUL-2018	53	6725	458	55	7291	0.73%	92.24%	6.28%	0.75%	100.00%
AUG-2018	54	6728	454	56	7292	0.74%	92.27%	6.23%	0.77%	100.00%
SEP-2018	52	6680	457	57	7246	0.72%	92.19%	6.31%	0.79%	100.00%
OCT-2018	53	6758	474	54	7339	0.72%	92.08%	6.46%	0.74%	100.00%
NOV-2018	53	6765	475	50	7343	0.72%	92.13%	6.47%	0.68%	100.00%
DEC-2018	52	6782	477	49	7360	0.71%	92.15%	6.48%	0.67%	100.00%
JAN-2019	54	6806	486	53	7399	0.73%	91.99%	6.57%	0.72%	100.00%
FEB-2019	52	6790	492	49	7383	0.70%	91.97%	6.66%	0.66%	100.00%
MAR-2019	58	6829	490	50	7427	0.78%	91.95%	6.60%	0.67%	100.00%
APR-2019	56	6791	491	48	7386	0.76%	91.94%	6.65%	0.65%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	10 36%	3315 47%	9 32%	3071 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3633 51%
FEB-2018	13 35%	3317 47%	12 32%	3075 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3583 51%
MAR-2018	10 37%	3339 47%	10 37%	3103 44%	0 0%	60 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	17 63%	3566 50%
APR-2018	5 23%	3347 47%	5 23%	3115 44%	0 0%	56 1%	0 0%	3 0%	0 0%	4 0%	2 9%	333 5%	15 68%	3538 50%
MAY-2018	9 39%	3356 48%	8 35%	3130 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3512 50%
JUN-2018	6 30%	3372 48%	6 30%	3148 45%	0 0%	54 1%	0 0%	5 0%	0 0%	3 0%	1 5%	380 5%	13 65%	3481 49%
JUL-2018	7 28%	3399 48%	7 28%	3176 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 16%	398 6%	14 56%	3448 49%
AUG-2018	13 33%	3395 48%	14 36%	3183 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	415 6%	23 59%	3415 48%
SEP-2018	4 15%	3378 48%	3 12%	3163 45%	1 4%	47 1%	0 0%	4 0%	0 0%	2 0%	4 15%	446 6%	18 69%	3367 48%
OCT-2018	11 31%	3419 48%	9 26%	3206 45%	1 3%	49 1%	0 0%	3 0%	0 0%	2 0%	0 0%	479 7%	25 71%	3382 47%
NOV-2018	9 35%	3428 48%	8 31%	3214 45%	0 0%	47 1%	0 0%	4 0%	0 0%	2 0%	1 4%	491 7%	17 65%	3353 47%
DEC-2018	8 32%	3446 48%	8 32%	3233 45%	0 0%	45 1%	0 0%	4 0%	0 0%	1 0%	2 8%	504 7%	15 60%	3350 47%
JAN-2019	8 23%	3471 48%	7 20%	3258 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3361 47%
FEB-2019	13 45%	3467 48%	12 41%	3266 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	542 8%	13 45%	3311 46%
MAR-2019	6 30%	3484 48%	6 30%	3287 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3314 46%
APR-2019	11 41%	3483 48%	11 41%	3291 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	587 8%	14 52%	3260 45%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial	%	All	%
JAN-2018	18	64%	3709	52%
FEB-2018	24	65%	3677	52%
MAR-2018	17	63%	3672	52%
APR-2018	17	77%	3660	52%
MAY-2018	14	61%	3658	52%
JUN-2018	14	70%	3659	52%
JUL-2018	18	72%	3651	52%
AUG-2018	25	64%	3648	52%
SEP-2018	22	85%	3627	51%
OCT-2018	24	69%	3683	52%
NOV-2018	17	65%	3669	51%
DEC-2018	17	68%	3671	51%
JAN-2019	27	77%	3700	51%
FEB-2019	16	55%	3680	51%
MAR-2019	14	70%	3710	51%
APR-2019	16	59%	3676	51%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	8 0%	3 30%	1315 45%	7 70%	1415 48%	0 0%	196 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1256 44%	15 100%	1421 49%	0 0%	190 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1245 43%	10 91%	1439 50%	0 0%	188 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1223 43%	11 100%	1437 50%	0 0%	182 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1208 43%	5 100%	1442 51%	0 0%	181 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1190 42%	11 92%	1431 51%	0 0%	176 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 20%	1171 42%	7 70%	1439 52%	1 10%	169 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1155 42%	11 69%	1424 52%	0 0%	166 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1132 42%	6 86%	1407 52%	0 0%	159 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
OCT-2018	0 0%	7 0%	3 17%	1121 41%	15 83%	1447 53%	0 0%	153 6%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
NOV-2018	0 0%	6 0%	1 14%	1116 41%	6 86%	1456 53%	0 0%	146 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
DEC-2018	0 0%	5 0%	1 11%	1106 41%	7 78%	1457 54%	1 11%	145 5%	0 0%	0 0%	0 0%	2 0%	0 0%	9 0%
JAN-2019	0 0%	6 0%	1 8%	1099 40%	11 92%	1478 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1071 40%	9 82%	1475 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1054 39%	3 60%	1487 55%	0 0%	133 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1033 39%	7 70%	1481 56%	2 20%	133 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%
OCT-2018	0	0%	1	0%
NOV-2018	0	0%	1	0%
DEC-2018	0	0%	1	0%
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	3 50%	779 37%	1 17%	262 12%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	770 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	1 33%	758 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	1 50%	745 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	1 50%	721 36%	0 0%	248 12%	0 0%	724 36%	1 50%	314 16%
JUL-2018	3 60%	723 36%	0 0%	243 12%	0 0%	717 36%	2 40%	314 16%
AUG-2018	2 100%	715 36%	0 0%	238 12%	0 0%	716 36%	0 0%	308 16%
SEP-2018	6 100%	706 36%	0 0%	236 12%	0 0%	712 36%	0 0%	311 16%
OCT-2018	3 60%	696 36%	0 0%	234 12%	0 0%	710 36%	2 40%	323 16%
NOV-2018	8 80%	687 35%	0 0%	230 12%	0 0%	700 36%	2 20%	323 17%
DEC-2018	1 100%	684 36%	0 0%	225 12%	0 0%	696 36%	0 0%	320 17%
JAN-2019	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	2 67%	668 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	3 75%	661 35%	0 0%	224 12%	1 25%	681 36%	0 0%	322 17%
APR-2019	4 100%	645 35%	0 0%	223 12%	0 0%	678 36%	0 0%	321 17%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	9 47%	2004 60%	8 42%	631 19%	0 0%	46 1%	2 11%	685 21%
FEB-2018	0 0%	0 0%	16 70%	2026 60%	6 26%	641 19%	0 0%	45 1%	1 4%	675 20%
MAR-2018	0 0%	0 0%	14 100%	2060 61%	0 0%	645 19%	0 0%	43 1%	0 0%	674 20%
APR-2018	0 0%	0 0%	8 67%	2104 61%	4 33%	654 19%	0 0%	44 1%	0 0%	681 20%
MAY-2018	0 0%	0 0%	13 65%	2139 61%	4 20%	665 19%	1 5%	42 1%	3 15%	675 19%
JUN-2018	0 0%	0 0%	7 64%	2172 62%	3 27%	675 19%	0 0%	42 1%	1 9%	676 19%
JUL-2018	0 0%	0 0%	7 58%	2207 62%	4 33%	674 19%	0 0%	43 1%	1 8%	675 19%
AUG-2018	0 0%	0 0%	23 79%	2254 62%	5 17%	675 19%	0 0%	42 1%	1 3%	671 19%
SEP-2018	0 0%	9 0%	5 36%	2261 62%	9 64%	689 19%	0 0%	41 1%	0 0%	655 18%
OCT-2018	0 0%	17 0%	13 76%	2318 63%	4 24%	708 19%	0 0%	40 1%	0 0%	658 18%
NOV-2018	0 0%	17 0%	11 100%	2344 63%	0 0%	704 19%	0 0%	38 1%	0 0%	650 17%
DEC-2018	0 0%	17 0%	13 76%	2367 63%	4 24%	720 19%	0 0%	39 1%	0 0%	652 17%
JAN-2019	0 0%	16 0%	15 75%	2430 63%	4 20%	730 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2440 63%	5 23%	727 19%	0 0%	40 1%	1 5%	653 17%
MAR-2019	0 0%	27 1%	8 62%	2492 64%	5 38%	747 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	7 54%	2508 64%	3 23%	740 19%	0 0%	36 1%	3 23%	636 16%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2018	2008	27.56	1645	22.58	2593	35.59	117	1.61	55	0.75	868	11.91
FEB-2018	1964	27.09	1630	22.48	2613	36.04	116	1.60	59	0.81	869	11.98
MAR-2018	1978	27.19	1616	22.21	2645	36.35	113	1.55	56	0.77	868	11.93
APR-2018	1936	26.66	1596	21.97	2697	37.13	114	1.57	58	0.80	862	11.87
MAY-2018	1927	26.45	1575	21.62	2737	37.57	114	1.56	58	0.80	874	12.00
JUN-2018	1910	26.21	1564	21.46	2789	38.27	113	1.55	58	0.80	854	11.72
JUL-2018	1886	25.87	1567	21.49	2818	38.65	110	1.51	55	0.75	855	11.73
AUG-2018	1863	25.55	1549	21.24	2862	39.25	111	1.52	56	0.77	851	11.67
SEP-2018	1827	25.21	1532	21.14	2878	39.72	109	1.50	57	0.79	843	11.63
OCT-2018	1850	25.21	1529	20.83	2946	40.14	104	1.42	54	0.74	856	11.66
NOV-2018	1842	25.09	1523	20.74	2967	40.41	106	1.44	50	0.68	855	11.64
DEC-2018	1835	24.93	1511	20.53	3006	40.84	104	1.41	49	0.67	855	11.62
JAN-2019	1834	24.79	1481	20.02	3063	41.40	100	1.35	53	0.72	868	11.73
FEB-2019	1805	24.45	1479	20.03	3083	41.76	99	1.34	49	0.66	868	11.76
MAR-2019	1796	24.18	1474	19.85	3139	42.26	99	1.33	50	0.67	869	11.70
APR-2019	1767	23.92	1461	19.78	3152	42.68	100	1.35	48	0.65	858	11.62

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	21	4	1	5	4	6	325
APR-2018	15	0	0	5	3	5	480
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	13	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405
OCT-2018	19	0	1	2	5	10	525
NOV-2018	9	2	2	2	0	2	185
DEC-2018	19	2	0	5	5	7	380
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	3	4	368

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2018	11958	3653
FEB-2018	11988	3668
MAR-2018	12016	3698
APR-2018	12047	3727
MAY-2018	12082	3752
JUN-2018	12094	3755
JUL-2018	12120	3779
AUG-2018	12134	3774
SEP-2018	12157	3795
OCT-2018	12179	3798
NOV-2018	12216	3817
DEC-2018	12220	3812
JAN-2019	12262	3839
FEB-2019	12274	3842
MAR-2019	12310	3878
APR-2019	12343	3907

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
April 2019

N = 7386

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2019

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2019

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2019

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2019

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2019

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	11	13	*
	50+	26	37	*
	Total HSDA:	43	56	31
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	73	96	53	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	367	492	279	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	14
	35-49	*	*	37
	50+	*	*	94
Total HSDA:	193	256	145	
Total HA:		676	900	508

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	65	66	*
	35-49	179	201	*
	50+	427	628	*
Total HA:		676	900	508

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	541	722	414
Female	135	178	94

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	508	54	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	11
	5 years or more	11	8
	<5 years	14	12
	Total HSDA:	43	31
KOOTENAY BOUNDARY	10 years or more	45	32
	5 years or more	14	10
	<5 years	14	11
	Total HSDA:	73	53
OKANAGAN	10 years or more	227	162
	5 years or more	66	54
	<5 years	74	63
	Total HSDA:	367	279
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	107	74
	5 years or more	41	36
	<5 years	45	35
	Total HSDA:	193	145
Total HA:		676	508

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	397	279
	5 years or more	132	108
	<5 years	147	121
Total HA:		676	508

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	41	59	13	25
KOOTENAY BOUNDARY	68	120	21	43
OKANAGAN	212	912	60	283
THOMPSON/CARIBOO/SHUSWAP	130	498	39	137
Total:	451	1589	133	488

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	100

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	5	5	5
	20-34	29	31	22
	35-49	108	119	82
	50+	219	292	172
	Total HSDA:	361	447	281
FRASER NORTH	0-19	10	10	*
	20-34	106	107	*
	35-49	354	388	*
	50+	534	852	*
	Total HSDA:	1004	1357	771
FRASER SOUTH	0-19	7	7	5
	20-34	114	116	85
	35-49	340	387	281
	50+	518	765	432
	Total HSDA:	979	1275	803
Total HA:		2344	3079	1855

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	22	22	12
	20-34	249	254	177
	35-49	802	894	634
	50+	1271	1909	1032
Total HA:		2344	3079	1855

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1778	2359	1436
Female	566	720	419

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1855	51	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	205	155
	5 years or more	80	66
	<5 years	76	60
	Total HSDA:	361	281
FRASER NORTH	10 years or more	539	388
	5 years or more	252	201
	<5 years	213	182
	Total HSDA:	1004	771
FRASER SOUTH	10 years or more	522	418
	5 years or more	226	182
	<5 years	231	203
	Total HSDA:	979	803
Total HA:		2344	1855

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1266	961
	5 years or more	558	449
	<5 years	520	445
Total HA:		2344	1855

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	139	488	34	67
FRASER NORTH	248	1547	50	246
FRASER SOUTH	212	1429	46	462
Total:	599	3464	130	775

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	188
FRASER NORTH	631
FRASER SOUTH	486
Total:	1305

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	20
	35-49	*	*	64
	50+	*	*	199
	Total HSDA:		335	481
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		167	216
VANCOUVER	0-19	34	36	6
	20-34	434	447	317
	35-49	1412	1588	1031
	50+	2763	4708	2085
	Total HSDA:	4643	6779	3439
Total HA:		5145	7476	3851

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	37	39	7
	20-34	485	499	356
	35-49	1533	1721	1127
	50+	3090	5217	2361
Total HA:		5145	7476	3851

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4533	6563	3407
Female	610	911	444

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3851	53	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	184	150
	5 years or more	80	67
	<5 years	71	66
	Total HSDA:	335	283
RICHMOND	10 years or more	*	67
	5 years or more	*	30
	<5 years	*	32
	Never on ART	*	0
Total HSDA:	167	129	
VANCOUVER	10 years or more	2665	1893
	5 years or more	1189	877
	<5 years	789	669
	Never on ART	0	0
Total HSDA:	4643	3439	
Total HA:	5145	3851	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	*	2110
5 years or more	*	974
<5 years	*	767
Never on ART	*	0
Total HA:	5145	3851

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	166	486	51	171
RICHMOND	43	284	11	93
VANCOUVER	589	10660	190	5285
Total:	798	11430	252	5549

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	116

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		315	445
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		122	163
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		728	1026
Total HA:		1165	1634	928

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	103	108	*
	35-49	316	367	*
	50+	740	1153	*
Total HA:		1165	1634	928

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	959	1344	764
Female	206	290	164

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	928	54	530	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	169	140
	5 years or more	72	61
	<5 years	74	59
	Total HSDA:	315	260
NORTH VANCOUVER ISLAND	10 years or more	68	59
	5 years or more	32	25
	<5 years	22	18
	Total HSDA:	122	102
SOUTH VANCOUVER ISLAND	10 years or more	413	298
	5 years or more	156	131
	<5 years	159	137
	Total HSDA:	728	566
Total HA:		1165	928

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	650	497
5 years or more	260	217
<5 years	255	214
Total HA:	1165	928

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	191	846	75	197
NORTH VANCOUVER ISLAND	134	262	46	76
SOUTH VANCOUVER ISLAND	209	1757	44	552
Total:	534	2865	165	825

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	51
NORTH VANCOUVER ISLAND	37
SOUTH VANCOUVER ISLAND	110
Total:	198

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		39	47
NORTH WEST	0-19	*	*	0
	20-34	*	*	9
	35-49	*	*	15
	50+	*	*	33
	Total HSDA:		72	110
NORTHERN INTERIOR	0-19	5	5	*
	20-34	18	20	*
	35-49	69	85	*
	50+	87	146	*
	Total HSDA:		179	256
Total HA:		290	413	205

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	32	35	*
	35-49	107	143	*
	50+	144	228	*
Total HA:		290	413	205

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	175	254	123
Female	115	159	82

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	205	51	530	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	17	8
	5 years or more	14	6
	<5 years	8	5
	Total HSDA:	39	19
NORTH WEST	10 years or more	31	21
	5 years or more	25	21
	<5 years	16	15
	Total HSDA:	72	57
NORTHERN INTERIOR	10 years or more	73	49
	5 years or more	59	50
	<5 years	47	30
	Total HSDA:	179	129
Total HA:		290	205

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	121	78
	5 years or more	98	77
	<5 years	71	50
Total HA:		290	205

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries NORTHERN Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	38	61	5	6
NORTH WEST	71	161	14	31
NORTHERN INTERIOR	104	449	15	172
Total:	213	671	34	209

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	23
NORTHERN INTERIOR	15
Total:	44

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	20	36	12
	THOMPSON/CARIBOO/SHUSWAP	27	45	19
	Total HA:	59	100	42
FRASER	FRASER EAST	41	51	32
	FRASER NORTH	54	90	45
	FRASER SOUTH	69	102	48
	Total HA:	164	243	125
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	49	23
	RICHMOND	12	17	8
	VANCOUVER	494	852	393
	Total HA:	532	918	424
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	50	78	40
	NORTH VANCOUVER ISLAND	17	26	16
	SOUTH VANCOUVER ISLAND	36	78	29
	Total HA:	103	182	85
NORTHERN	NORTH EAST	10	12	6
	NORTH WEST	32	61	25
	NORTHERN INTERIOR	63	100	51
	Total HA:	105	173	82
Total:		963	1616	758

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	600	1029	472
Female	363	587	286

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	758	51	500	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by





blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

